BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-113@pharmaconomics
DTSTAMP:20260707T004903Z
DTSTART;VALUE=DATE:20260730
DTEND;VALUE=DATE:20260731
SUMMARY:MRTX Phase 2 — Adagrasib
DESCRIPTION:Phase 2 trial results for Adagrasib in Advanced Cancer are due Jul 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT05853575\n\nTrack it: https://www.pharmaconomics.com/e/113
URL:https://www.pharmaconomics.com/e/113
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MRTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR